nortriptyline has been researched along with Parkinson Disease in 14 studies
Nortriptyline: A metabolite of AMITRIPTYLINE that is also used as an antidepressive agent. Nortriptyline is used in major depression, dysthymia, and atypical depressions.
nortriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(methylamino)propylidene group at position 5. It is an active metabolite of amitriptyline.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
Excerpt | Relevance | Reference |
---|---|---|
" In a 14-week randomized trial comparing pramipexole with sertraline in depressed patients without motor complications, the Hamilton Depression Rating Scale score decreased in both groups; however, in the pramipexole group, the proportion of patients who recovered was significantly higher." | 4.87 | Treatment of depressive symptoms in Parkinson's disease. ( Barone, P, 2011) |
"Fifty-two depressed Parkinson's disease patients were enrolled in an NIH-funded randomized, controlled trial of nortriptyline, paroxetine, and placebo." | 2.75 | The impact of antidepressant treatment on cognitive functioning in depressed patients with Parkinson's disease. ( Bienfait, KL; Dicke, A; Dobkin, RD; Gara, M; Marin, H; Mark, MH; Menza, M; Tröster, A, 2010) |
"Nortriptyline was superior to placebo for the change in HAM-D (p < 0." | 2.74 | A controlled trial of antidepressants in patients with Parkinson disease and depression. ( Bienfait, K; Buyske, S; Dicke, A; Dobkin, RD; Gara, M; Marin, H; Mark, MH; Menza, M, 2009) |
"It suggests that successfully treating depression in PD leads to important, sustained improvements in these outcomes and that patients who improve on antidepressants are less likely to relapse than are patients who initially improve on placebo." | 2.74 | The impact of treatment of depression on quality of life, disability and relapse in patients with Parkinson's disease. ( Bienfait, K; Buyske, S; Dicke, A; Dobkin, RD; Gara, M; Marin, H; Mark, MH; Menza, M, 2009) |
"The authors suggest the depression in Parkinson's disease to be of both reactive and endogenous origins." | 2.65 | Anti-depressive treatment in Parkinson's disease. A controlled trial of the effect of nortriptyline in patients with Parkinson's disease treated with L-DOPA. ( Aabro, E; Andersen, J; Gulmann, N; Hjelmsted, A; Pedersen, HE, 1980) |
"Although anxiety is associated with Parkinson's disease, anxiety disorders can begin before the onset of motor symptoms, and have been linked to a possible abnormality of dopaminergic, serotonergic, and adrenergic neurons that precedes motor disturbance." | 2.58 | Pharmacological interventions for anxiety in Parkinson's disease sufferers. ( Kohsaka, M; Oeda, T; Park, K; Sawada, H; Tomita, S; Umemura, A; Yamamoto, K, 2018) |
"Dementia is a disorder that is characterized by a chronic, progressive loss of cognitive function." | 1.39 | Prescription patterns of anticholinergic agents and their associated factors in Korean elderly patients with dementia. ( Lee, EK; Lee, YJ, 2013) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 4 (28.57) | 18.7374 |
1990's | 1 (7.14) | 18.2507 |
2000's | 3 (21.43) | 29.6817 |
2010's | 5 (35.71) | 24.3611 |
2020's | 1 (7.14) | 2.80 |
Authors | Studies |
---|---|
Schrag, A | 2 |
Carroll, C | 2 |
Duncan, G | 2 |
Molloy, S | 2 |
Grover, L | 2 |
Hunter, R | 2 |
Brown, R | 2 |
Freemantle, N | 2 |
Whipps, J | 2 |
Serfaty, MA | 2 |
Lewis, G | 2 |
Sawada, H | 1 |
Umemura, A | 1 |
Kohsaka, M | 1 |
Tomita, S | 1 |
Park, K | 1 |
Oeda, T | 1 |
Yamamoto, K | 1 |
Lee, EK | 1 |
Lee, YJ | 1 |
Menza, M | 4 |
Dobkin, RD | 4 |
Marin, H | 4 |
Mark, MH | 4 |
Gara, M | 4 |
Buyske, S | 2 |
Bienfait, K | 2 |
Dicke, A | 4 |
Bienfait, KL | 2 |
Tröster, A | 1 |
Friedman, J | 1 |
Barone, P | 1 |
Andersen, J | 1 |
Aabro, E | 1 |
Gulmann, N | 1 |
Hjelmsted, A | 1 |
Pedersen, HE | 1 |
Hinds, NP | 1 |
Hillier, CE | 1 |
Wiles, CM | 1 |
Gabriel, E | 1 |
Karobath, M | 1 |
Lenz, G | 1 |
Driver, PS | 1 |
Harvey, NS | 1 |
Patni, SK | 1 |
Dandiya, PC | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Treatment of Depression in Patients With Parkinson's Disease[NCT00062738] | Phase 2 | 52 participants (Actual) | Interventional | 2003-06-30 | Completed | ||
Study of Antidepressants in Parkinson's Disease[NCT00086190] | Phase 3 | 115 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
total score on HDRS (0-54 higher score is worse) (NCT00062738)
Timeframe: 8 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
Nortriptyline | 10.84 |
Paroxetine | 12.45 |
Placebo | 15.81 |
Percent of patients who had a 50% decrease in total HDRS at 8 weeks (NCT00062738)
Timeframe: 8 weeks
Intervention | percent of patients who were responders (Number) |
---|---|
Nortriptyline | 53 |
Paroxetine | 11 |
Placebo | 24 |
Beck Depression Inventory II ranges from 0-63. Higher score indicates more severe depression. 0-13 minimal depression, 14-19 mild depression, 20-28 moderate depression, 29-63 severe depression. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
Intervention | Change in BDI-II score (Mean) |
---|---|
Paroxetine | -9.7 |
Venlafaxine Extended Release | -9.6 |
Placebo | -5.2 |
Brief Psychiatric Rating Scale. Maximum score 126. Higher score indicates greater psychiatric difficulties. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
Intervention | Change in BPRS score (Mean) |
---|---|
Paroxetine | -9.0 |
Venlafaxine Extended Release | -9.8 |
Placebo | -4.4 |
Geriatric Depression Scale ranges from 0-30. Higher score indicates more severe depression. 0-9 normal, 10-19 mild depression, 20-30 severe depression. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
Intervention | Change in GDS score (Mean) |
---|---|
Paroxetine | -6.9 |
Venlafaxine Extended Release | -6.9 |
Placebo | -2.8 |
Change in Hamilton Rating Scale for Depression over 12 weeks. Hamilton Depression Rating Scale ranges from 0-50. Higher scores represent more significant depression. Mild depression ranges from 8-13, moderate depression from 14-18, severe 19-22 and very severe any score over 23. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
Intervention | Change in HAM-D score (Mean) |
---|---|
Paroxetine | -13.0 |
Venlafaxine Extended Release | -11.0 |
Placebo | -6.8 |
Montgomery-Asberg Depression Rating Scale ranges from 0-60. Higher score indicates more severe depression. 0-6 normal, 7-19 mild depression, 20-34 moderate depression, greater than 34 severe depression. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
Intervention | Change in MADRS score (Mean) |
---|---|
Paroxetine | -13.6 |
Venlafaxine Extended Release | -10.9 |
Placebo | -6.6 |
Parkinson's Disease Questionnaire (PDQ-39) - Emotional Well-Being maximum score 24, minimum score of 0.Lower score indicates a better perceived health status. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
Intervention | Change in PDQ-39 Emotional score (Mean) |
---|---|
Paroxetine | -21.4 |
Venlafaxine Extended Release | -20.7 |
Placebo | -10.9 |
Parkinson's Disease Questionnaire (PDQ-39) Total. Range 0-100. Lower score indicates a better perceived health status. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
Intervention | Change in PDQ-39 score (Mean) |
---|---|
Paroxetine | -8.0 |
Venlafaxine Extended Release | -8.4 |
Placebo | -5.3 |
Pittsburgh Sleep Quality Index scores range from 0-21, with higher scores indicating severe sleep difficulties. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
Intervention | Change in PQSI score (Mean) |
---|---|
Paroxetine | -2.1 |
Venlafaxine Extended Release | -2.6 |
Placebo | -1.1 |
Short Form 36 Health Survey. Range 0-100. Higher score indicates a better perceived quality of life. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
Intervention | Change in SF-36 mental score (Mean) |
---|---|
Paroxetine | 11.4 |
Venlafaxine Extended Release | 9.5 |
Placebo | 4.8 |
Short Form 36 Health Survey - Mental Health subscale ranges from 0-100. Higher score indicates a better perceived quality of life. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
Intervention | Change in SF-36 Mental Health score (Mean) |
---|---|
Paroxetine | 16.7 |
Venlafaxine Extended Release | 17.4 |
Placebo | 9.7 |
Short Form 36 Health Survey - Emotional subscale ranges from 0-100. Higher score indicates a better perceived quality of life. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
Intervention | Change in SF-36 Role score (Mean) |
---|---|
Paroxetine | 39.5 |
Venlafaxine Extended Release | 26.9 |
Placebo | 12.7 |
Short Form 36 Health Survey - Vitality subscale ranges from 0-100. Higher score indicates a better perceived quality of life. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
Intervention | Change in SF-36 vitality score (Mean) |
---|---|
Paroxetine | 13.5 |
Venlafaxine Extended Release | 9.1 |
Placebo | 4.7 |
Snaith Clinical Anxiety Scale. Range 0-21. Higher scores indicate increased anxiety. Score greater than 8 indicates clinical anxiety. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
Intervention | Change in CAS score (Mean) |
---|---|
Paroxetine | -3.6 |
Venlafaxine Extended Release | -3.2 |
Placebo | -2.4 |
Unified Parkinson's Disease Rating Scale. Higher score indicates more severe Parkinson's disease symptoms. Total maximum = 176. Mental maximum = 52, Activities of Daily Living maximum = 52, Motor maximum = 72. Minimum = 0. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
Intervention | Change in UPDRS score (Mean) |
---|---|
Paroxetine | -8.7 |
Venlafaxine Extended Release | -7.0 |
Placebo | -4.3 |
Unified Parkinson's Disease Rating Scale - Bulbar maximum score 24, minimum score of 0. Higher score indicates more severe Parkinson's disease symptoms. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
Intervention | Change in UPDRS-Bulbar score (Mean) |
---|---|
Paroxetine | -1.4 |
Venlafaxine Extended Release | -1.4 |
Placebo | -0.5 |
Unified Parkinson's Disease Rating Scale - Motor has a maximum score of 72, minimum score of 0. Higher score indicates more severe Parkinson's disease symptoms. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
Intervention | Change in UPDRS-motor score (Mean) |
---|---|
Paroxetine | -4.3 |
Venlafaxine Extended Release | -2.0 |
Placebo | -1.0 |
Unified Parkinson's Disease Rating Scale - Tremor subscale ranges from 0-23. Higher score indicates more severe Parkinson's disease symptoms. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
Intervention | Change in UPDRS-tremor score (Mean) |
---|---|
Paroxetine | 0.4 |
Venlafaxine Extended Release | 0.5 |
Placebo | -0.6 |
3 reviews available for nortriptyline and Parkinson Disease
Article | Year |
---|---|
Pharmacological interventions for anxiety in Parkinson's disease sufferers.
Topics: Antidepressive Agents, Tricyclic; Anxiety Disorders; Dopamine; Dopamine Agonists; Humans; Nortriptyl | 2018 |
Treatment of depressive symptoms in Parkinson's disease.
Topics: Antidepressive Agents, Tricyclic; Antiparkinson Agents; Benzothiazoles; Depression; Desipramine; Dop | 2011 |
Psychiatric disorders in parkinsonism. 1. Functional illnesses and personality.
Topics: Antidepressive Agents; Clozapine; Depressive Disorder; Dopamine; Electroconvulsive Therapy; Female; | 1986 |
7 trials available for nortriptyline and Parkinson Disease
Article | Year |
---|---|
Antidepressants Trial in Parkinson's Disease (ADepT-PD): protocol for a randomised placebo-controlled trial on the effectiveness of escitalopram and nortriptyline on depressive symptoms in Parkinson's disease.
Topics: Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Escitalopram; Humans; Multic | 2022 |
Antidepressants Trial in Parkinson's Disease (ADepT-PD): protocol for a randomised placebo-controlled trial on the effectiveness of escitalopram and nortriptyline on depressive symptoms in Parkinson's disease.
Topics: Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Escitalopram; Humans; Multic | 2022 |
Antidepressants Trial in Parkinson's Disease (ADepT-PD): protocol for a randomised placebo-controlled trial on the effectiveness of escitalopram and nortriptyline on depressive symptoms in Parkinson's disease.
Topics: Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Escitalopram; Humans; Multic | 2022 |
Antidepressants Trial in Parkinson's Disease (ADepT-PD): protocol for a randomised placebo-controlled trial on the effectiveness of escitalopram and nortriptyline on depressive symptoms in Parkinson's disease.
Topics: Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Escitalopram; Humans; Multic | 2022 |
A controlled trial of antidepressants in patients with Parkinson disease and depression.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents; Antidepressive Agents, Tricyclic; Anxiety; Co | 2009 |
A controlled trial of antidepressants in patients with Parkinson disease and depression.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents; Antidepressive Agents, Tricyclic; Anxiety; Co | 2009 |
A controlled trial of antidepressants in patients with Parkinson disease and depression.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents; Antidepressive Agents, Tricyclic; Anxiety; Co | 2009 |
A controlled trial of antidepressants in patients with Parkinson disease and depression.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents; Antidepressive Agents, Tricyclic; Anxiety; Co | 2009 |
The impact of treatment of depression on quality of life, disability and relapse in patients with Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents; Depression; Disability Evaluation; Double-Bli | 2009 |
The impact of antidepressant treatment on cognitive functioning in depressed patients with Parkinson's disease.
Topics: Adult; Aged, 80 and over; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepre | 2010 |
Depression in Parkinson's disease: symptom improvement and residual symptoms after acute pharmacologic management.
Topics: Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Dysthymic Disorder; Female; | 2011 |
Anti-depressive treatment in Parkinson's disease. A controlled trial of the effect of nortriptyline in patients with Parkinson's disease treated with L-DOPA.
Topics: Aged; Clinical Trials as Topic; Depression; Double-Blind Method; Drug Therapy, Combination; Female; | 1980 |
Depression treatment in Parkinson's disease.
Topics: Antidepressive Agents, Tricyclic; Carbidopa; Depression; Double-Blind Method; Drug Interactions; Dru | 1991 |
4 other studies available for nortriptyline and Parkinson Disease
Article | Year |
---|---|
Prescription patterns of anticholinergic agents and their associated factors in Korean elderly patients with dementia.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Cholinergic Antagonists; Comorbidity; Dementia; Elect | 2013 |
Possible serotonin syndrome arising from an interaction between nortriptyline and selegiline in a lady with parkinsonism.
Topics: Antidepressive Agents, Tricyclic; Antiparkinson Agents; Depressive Disorder; Drug Interactions; Fema | 2000 |
[The extrapyramidal symptoms in the combination of lithium long-term lithium therapy with nortriptyline. A case report on the formation of a pathogenesis hypothesis].
Topics: Adult; Basal Ganglia Diseases; Bipolar Disorder; Chlorprothixene; Clopenthixol; Dibenzazepines; Drug | 1976 |
The influence of monoamine oxidase inhibitors and some other antidepressants on the anti-parkinsonian activity of sub-effective doses of diphenylhydramine in rats and mice.
Topics: Animals; Antidepressive Agents; Catatonia; Diphenhydramine; Humans; Mice; Monoamine Oxidase Inhibito | 1972 |